

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This listing of the claims replaces all prior listings.

1. (Currently Amended) A poxvirus expression vector for expressing the BFA4 protein in a cell, the vector comprising the nucleic acid sequence as illustrated in of SEQ ID NO.: 1, or an immunoreactive fragment thereof wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein capable of inducing or enhancing an immune response against the encoded proteins or peptides.
- 2-3. (Cancelled)
4. (Currently Amended) The expression vector of claim 1 wherein the viral vector is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5. (Currently Amended) The expression vector of claim 4 wherein the viral vector is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6. (Previously Presented) The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.
- 7-8. (Cancelled)
9. (Currently Amended) The expression vector of claim 6 wherein the viral vector is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10. (Currently Amended) The expression vector of claim 9 wherein the viral vector is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
11. (Original) The expression vector of claim 1 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
- 12-13. (Cancelled)
14. (Currently Amended) The expression vector of claim 11 wherein the viral vector is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
15. (Currently Amended) The expression vector of claim 14 wherein the viral vector is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

16. (Original) The expression vector of claim 6 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
- 17-18. (Canceled)
19. (Currently Amended) The expression vector of claim 16 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
20. (Currently Amended) The poxvirus of claim 19 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
21. (Previously Presented) The expression vector of claim 1, 6, 11 and 16 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
- 22-23. (Canceled)
24. (Currently Amended) The expression vector of claim 21 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
25. (Currently Amended) The poxvirus of claim 24 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
26. (Currently Amended) A composition comprising ~~a~~ the poxvirus expression vector of claim 1 ~~and in~~ a pharmaceutically acceptable carrier, ~~said vector comprising the nucleic acid sequence shown in SEQ ID NO.: 1 or an immunoreactive fragment thereof capable of inducing or enhancing an immune response against the encoded proteins or peptides.~~
- 27-28. (Canceled)
29. (Currently Amended) The expression vector of claim 26 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
30. (Currently Amended) The poxvirus of claim 29 wherein the ~~viral vector is a~~ poxvirus ~~is~~ selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
- 31-39. (Canceled)
40. (Previously Presented) The expression vector of claim 6 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.
41. (Previously Presented) The expression vector of claim 11 further comprising at least one additional nucleic acid sequence encoding a tumor-associated antigen having the amino acid sequence of SEQ ID NO:4.

42. (Previously Presented) The expression vector of claim 16 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.
43. (Previously Presented) The expression vector of claim 21 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.
44. (Currently Amended) A poxvirus expression vector comprising a nucleic acid sequence encoding a polypeptide BFA4 protein having the amino acid sequence of SEQ ID NO:2, the expression vector capable of inducing or enhancing an immune response against the encoded polypeptide wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.
- 45-46. (Canceled)
47. (Currently Amended) The expression vector of claim 44 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
48. (Currently Amended) The expression vector of claim 47 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
49. (Previously Presented) The expression vector of claim 44 further comprising a nucleic acid encoding at least one additional tumor-associated antigen.
- 50-51. (Canceled)
52. (Currently Amended) The expression vector of claim 49 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
53. (Currently Amended) The expression vector of claim 52 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
54. (Previously Presented) The expression vector of claim 44 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
- 55-56. (Canceled)
57. (Currently Amended) The expression vector of claim 54 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
58. (Currently Amended) The expression vector of claim 57 wherein the ~~viral vector~~ is a poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

59. (Previously Presented) The expression vector selected from the group consisting of the expression vector of claims 44, 49 and 54 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
- 60-61. (Canceled)
62. (Currently Amended) The expression vector of claim 59 wherein the ~~viral vector is a poxvirus~~ is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
63. (Currently Amended) The poxvirus of claim 62 wherein the ~~viral vector is a poxvirus~~ is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
64. (Currently Amended) A ~~pharmaceutical~~-composition comprising an expression vector of claim 44 and a pharmaceutically acceptable carrier.
65. (Currently Amended) A ~~pharmaceutical~~ composition comprising an expression vector of claim 49 and a pharmaceutically acceptable carrier.
66. (Currently Amended) A ~~pharmaceutical~~-composition comprising an expression vector of claim 54 and a pharmaceutically acceptable carrier.